Colette Blanchard
Adult Health · Baton Rouge, LANPI 1104814961
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,937 of the $5,695 with a category attached, or 69.1%. It is spread thinly across 31 manufacturers, the largest accounting for just 21.2%. Reporting peaked in 2022 at $2,640 and has fallen 54.4% since, to $1,203 in 2025.
Across 116 payments — averaging $49.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Astellas Pharma US Inc$736
- Shield Therapeutics Inc$493
- AbbVie$308
- Sage Therapeutics, LLC$260
- Phathom Pharmaceuticals, Inc.$250
- plus $2K from 25 others
What the payments were for
- Consulting fees$5409%
- Speaking & faculty fees$1,02018%
- Food & beverage$3,93769%
- Education$1983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 9 | $1,205 |
| Astellas Pharma US Inc | 25 | $736 |
| Shield Therapeutics Inc | 2 | $493 |
| AbbVie | 13 | $308 |
| Sage Therapeutics, LLC | 9 | $260 |
| Phathom Pharmaceuticals, Inc. | 2 | $250 |
| Abbott | 2 | $238 |
| Amgen | 7 | $223 |
| Neurelis, Inc. | 2 | $213 |
| Lilly USA, LLC | 2 | $186 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $176 |
| Organon | 8 | $148 |
| Johnson & Johnson | 1 | $146 |
| Bayer | 8 | $132 |
| Novo Nordisk | 2 | $120 |
| Kyowa Kirin, Inc. | 1 | $118 |
| Tris Pharma Inc | 1 | $102 |
| Biogen | 1 | $100 |
| Teva Pharmaceuticals USA, Inc. | 1 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $94 |
| Sumitomo Pharma America, Inc. | 2 | $81 |
| Medtronic | 3 | $50 |
| Millicent US Inc | 2 | $40 |
| Pacira Pharmaceuticals Incorporated | 2 | $35 |
| Myovant Sciences Inc. | 2 | $31 |
| Dexcom, Inc. | 1 | $25 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Coopersurgical, Inc. | 1 | $19 |
| Evofem Biosciences, Inc. | 1 | $19 |
| Merck | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYFEMBREE$1,080
- ACCRUFER$480
- VOQUEZNA$250
- FreeStyle Libre 2$123
- VALTOCO$121
- Veozah$119
- EVENITY$117
- FREESTYLE LIBRE 3$115
- Saxenda$105
- Dyanavel XR$102
- VRAYLAR$101
- Zurzuvae$100
How this compares
$5,695 in reported general payments places this provider in the 80th percentile of 203 adult health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 16 | $6,819 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $5,928 |
| Estradiol | 105 | $4,614 |
| DottiEstradiol | 14 | $1,270 |
| Estradiol (Twice Weekly)Estradiol | 11 | $1,101 |
| YuvafemEstradiol | 13 | $645 |
| Nystatin | 58 | $554 |
| Alendronate Sodium | 71 | $520 |
| ValacyclovirValacyclovir Hcl | 21 | $416 |
| Bupropion XlBupropion Hcl | 19 | $384 |
| Oxybutynin Chloride ErOxybutynin Chloride | 20 | $328 |
| Terconazole | 11 | $306 |
| ProgesteroneProgesterone, Micronized | 14 | $263 |
| Acyclovir | 18 | $252 |
| Clobetasol Propionate | 14 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $1,205 | $6,81916 claims |
| MerckJanumet Xr | $15 | $5,92811 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $96 | $25218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 203 adult health providers in Louisiana.
Other adult health in Baton Rouge
- Joan SmithBaton Rouge$121K
- Deborah SmithBaton Rouge$18K
- Tanisha SmithBaton Rouge$17K
- Eva Marina StaffordBaton Rouge$15K
- Dustin DenicolaBaton Rouge$14K
- Wendy GillBaton Rouge$13K
- Jennifer LeblancBaton Rouge$12K
- Carrie PerryBaton Rouge$6K
- Auldyn HirscheyBaton Rouge$6K
- Stephanie AkunneBaton Rouge$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.